Next-Generation DNA-Based Delivery of Therapeutic Proteins Using MYO Technology: Preclinical Results on Incretin Receptor Agonists
Time: 2:30 pm
day: Day Two
Details:
- MYO Technology platform consists of therapeutic-encoding plasmid DNA (pDNA) and a proprietary medical device for the intramuscular injection of pDNA and the delivery of electrical pulses promoting the in vivo electroporation of muscle cells and uptake of pDNA, leading to production, secretion, and uptake of the therapeutic protein into peripheral circulation
- MYO Technology has been developed to overcome some of the drawbacks that limit access to many therapeutic proteins, such as: i) high manufacturing costs; ii) administration via time-consuming infusions; iii) frequent dosing, sometimes even daily; iv) requirements for low temperature storage
- Animal proof-of-concept studies demonstrate that expression of MYO Technology delivered incretin receptor agonists is pDNA-dose dependent and remains stable for several months or longer in vivo. Importantly, MYO Technology-produced incretin receptor agonists are functional and efficacious in promoting weight and glucose control in animal models of diet-induced obesity
